Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-04 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL COMMERCIAL FOR THE THREE MONTHS ENDED 31 MARCH 2026 IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES IN THE PRC
Regulatory Filings
2026-04-30 English
2025 Sustainability Report
Environmental & Social Information Classification · 92% confidence The document is a full-length (249K characters) Environmental, Social and Governance (ESG) report titled “2025 Environmental, Social and Governance Report” by China Resources Pharmaceutical Group Limited. It covers sustainability philosophy, performance metrics, reporting standards (GRI, HKEX ESG Code, SASAC), Assurance Statement, Chairman’s message on ESG, governance statements, performance indicators, etc. This is a detailed ESG/sustainability report, fitting the “Environmental & Social Information” category (SR).
2026-04-28 English
2025 Annual Report
Regulatory Filings
2026-04-28 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR BOYA BIO-PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2026
Earnings Release Classification · 90% confidence The document is an announcement disclosing key unaudited quarterly financial results (revenue, net profit, cash flows, assets and liabilities) for the three months ended 31 March 2026. It provides only summary figures and refers readers to the full quarterly report on the exchange’s website. This matches the definition of an Earnings Release (ER) as an initial announcement of periodical financial results with key highlights only. Q1 2026
2026-04-24 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF KPC FOR THE THREE MONTHS ENDED 31 MARCH 2026
Earnings Release Classification · 90% confidence The document is a Hong Kong Exchange announcement titled “UNAUDITED FINANCIAL RESULTS OF KPC FOR THE THREE MONTHS ENDED 31 MARCH 2026,” providing key quarterly financial highlights (revenue, net profit, assets, liabilities) without the full interim report. It is a concise announcement of quarterly financial results (key metrics only), matching the definition of an Earnings Release (ER). Q1 2026
2026-04-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.